title: Mallory body induction in drug-primed mouse liver.
abstract: The aim of this study was to determine the various factors that are involved in the induction of Mallory body (MB) formation. A model was developed where MB formation was induced by refeeding either of the drugs griseofulvin or diethyl 1,4-dihydro-1,4,6-trimethyl-3,5-pyridinedicarboxylate (DDC). Mice were fed the drugs for 5 months, followed by withdrawal of the drugs for 1 month (drug-primed livers). The drugs were refed for 1,3,5,7, or 11 days. Early MBs first appeared as small, enlarged aggregates of filaments in the perinuclear or pericanalicular location on the third day of refeeding. Mature MBs appeared on the fifth day of refeeding. MBs reached maximum concentration on day 5 of refeeding. Western blots showed a progressive increase in the cytokeratin proteins (CK49 and CK55) and actin while refeeding the drugs. Liver cell regeneration, as indicated by the percent of proliferating cell nuclear antigen (PCNA)-positive nuclei, increased on the third day of refeeding. However, there was no correlation between the frequency of MBs and the percent of PCNA-positive nuclei. It is concluded that MB formation is not related to the liver cell regeneration response to injury but rather involves a separate regulation pathway. The MBs were heavily ubiquitinated and were associated with increased ubiquitin-protein conjugates as indicated by Western blotting, suggesting that ubiquitinization of cytokeratin protein are involved in the formation of MB aggregation.
authors.affiliation: Department of Pathology, Harbor-UCLA Medical Center, Torrance, CA, USA.
authors.forename: Q X
authors.initials: QX
authors.lastname: Yuan
authors.forename: N
authors.initials: N
authors.lastname: Marceau
authors.forename: B A
authors.initials: BA
authors.lastname: French
authors.forename: P
authors.initials: P
authors.lastname: Fu
authors.forename: S W
authors.initials: SW
authors.lastname: French
mesh_terms: D000818:Animals; D015153:Blotting, Western; D004095:Dihydropyridines / Q000494:pharmacology*; D006118:Griseofulvin / Q000494:pharmacology*; D002479:Inclusion Bodies / Q000378:metabolism / Q000648:ultrastructure*; D007633:Keratins / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000648:ultrastructure*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D008854:Microscopy, Electron; D011506:Proteins / Q000378:metabolism
chemical_list: D004095:Dihydropyridines; D011506:Proteins; C061879:diethyl 1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate; D006118:Griseofulvin; D007633:Keratins